ELTX
What one share of Elicio Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers.
Elicio Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.17 |
|---|---|
| Cash and investments | $1.07 |
| Debt | $0.44 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.20 | −$5.43 | $0.00 | −$1.55 | — | −$5.91 |
| 2021 | $1.00 | −$1.93 | $0.01 | −$1.88 | — | −$2.49 |
| 2022 | $7.28 | −$89.27 | $2.07 | −$72.26 | — | −$318.92 |
| 2023 | — | −$6.96 | $0.01 | −$6.48 | — | $1.18 |
| 2024 | — | −$4.25 | $0.01 | −$3.04 | — | −$1.03 |
| 2025 | — | −$2.58 | $0.00 | −$2.41 | — | $0.09 |